Webb, David J.
Coll, Blai
Heerspink, Hiddo J. L.
Andress, Dennis
Pritchett, Yili
Brennan, John J.
Houser, Mark
Correa-Rotter, Ricardo
Kohan, Donald
Makino, Hirofumi
Perkovic, Vlado
Remuzzi, Giuseppe
Tobe, Sheldon W.
Toto, Robert
Busch, Robert
Pergola, Pablo
Parving, Hans-Henrik
de Zeeuw, Dick
Funding for this research was provided by:
AbbVie
Article History
First Online: 22 August 2017
Compliance with Ethical Standards
:
: The study was conducted in accordance with the International Conference on Harmonisation guidelines, applicable regulations, and the principles of the Declaration of Helsinki. The study protocol was approved by an independent ethics committee or institutional review board.
: All patients provided written informed consent.
: AbbVie funded the study and was responsible for the study design, research, analysis, and data collection. The authors were responsible for interpretation of data, for writing, reviewing, and approving the manuscript and for determining the final content. No payments were made to the authors for writing this paper. Editorial support was provided by Richard M. Edwards, PhD, of Complete Publication Solutions, LLC (North Wales, PA, USA), a CHC Group company, and was funded by AbbVie.
: DJW is a consultant for AbbVie and has been a member of the independent data monitoring boards for the SONAR (Study Of diabetic Nephropathy with AtRasentan) and RADAR (Reducing residual Albuminuria in subjects with Diabetes and nephropathy With AtRasentan) clinical trials. RB serves on the speakers’ bureau of AbbVie, Merck, Bristol-Myers Squibb, Novo Nordisk, Daiichi Sankyo, Takeda, Eli Lilly, and Sanofi. PP is a consultant for AbbVie. DdZ is a consultant for and receives honoraria (to employer) from AbbVie, Astellas, AstraZeneca, Chemocentryx, J&J, Hemocue, Novartis, Reata, Takeda, and Vitae. RC-R has consultancy agreements with Roche, AbbVie, Amgen, AstraZeneca, and Boehringer Ingelheim; in the last 2 years he has served on the speakers’ bureau of Amgen, Roche, and Sanofi, and received grant support from Fibrogen and Janssen. DK is a consultant for AbbVie. HJLH is a consultant for and receives honoraria (to employer) from AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius, and Janssen. HM is a consultant for AbbVie and Teijin; receives speaker honoraria from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Pfizer, Takeda, and Tanabe Mitsubishi; and receives grant support from Astellas, Boehringer Ingelheim, Daiichi Sankyo, Dainippon Sumitomo, Kowa, Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Ono, Otsuka, Pfizer, Taishyo-Toyama, Takeda, Teijin, and Tanabe Mitsubishi. VP is a consultant for AbbVie, Astellas, AstraZeneca, Boehringer, Janssen, Roche, Servier, Merck, and Vitae. His employer receives funding/contracts for clinical trials from AbbVie, Baxter, Fresenius, Novartis, Pfizer, Resmed, Roche, Janssen, and Servier. YP is a former employee of Abbott and owns AbbVie stocks. GR is a consultant for Alexion, Reata, Bayer, Novartis, and AbbVie. All compensations are paid to his institution for research and educational activities. SWT is a consultant for AbbVie and received honoraria for academic talks from Servier. He is an investigator on both contract and investigator-initiated research projects with AstraZeneca, Bristol-Myers Squibb, Mitsubishi, and Pfizer. RT serves on advisory boards for Boehringer Ingelheim, Amgen, Relypsa, ZS Pharma, Bayer, Quintiles, and AstraZeneca. H-HP is a consultant for AbbVie. BC, DA, JJB, and MH are all AbbVie employees and own AbbVie stock.